Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Lita Araujo, Srikanth Kyatham, Kristen G Bzdek, Keiko Higuchi & Nupur Greene. (2023) Assessing the Health Economic Outcomes from Commercially Insured Relapsing Multiple Sclerosis Patients Who Switched from Other Disease-Modifying Therapies to Teriflunomide, in the United States. ClinicoEconomics and Outcomes Research 15, pages 361-373.
Read now
Read now
Emma van Eijndhoven, Michelle Brauer, Rebecca Kee, Joanna MacEwan, Lisa Mucha, Schiffon L. Wong, Adeline Durand & Jason Shafrin. (2020) Modeling the impact of patient treatment preference on health outcomes in relapsing-remitting multiple sclerosis. Journal of Medical Economics 23:5, pages 474-483.
Read now
Read now
Juan Carlos Torre-Alonso, Rubén Queiro, Marta Comellas, Luís Lizán & Carles Blanch. (2018) Patient-reported outcomes in European spondyloarthritis patients: a systematic review of the literature. Patient Preference and Adherence 12, pages 733-747.
Read now
Read now
María Dolores Edo Solsona, Emilio Monte Boquet, Bonaventura Casanova Estruch & José Luis Poveda Andrés. (2017) Impact of adherence on subcutaneous interferon beta-1a effectiveness administered by Rebismart® in patients with multiple sclerosis. Patient Preference and Adherence 11, pages 415-421.
Read now
Read now
Mar Tintoré, Maggie Alexander, Kathleen Costello, Martin Duddy, David E Jones, Nancy Law, Gilmore O’Neill, Antonio Uccelli, Robert Weissert & Sibyl Wray. (2017) The state of multiple sclerosis: current insight into the patient/health care provider relationship, treatment challenges, and satisfaction. Patient Preference and Adherence 11, pages 33-45.
Read now
Read now
Jack Burks, Thomas S Marshall & Xiaolan Ye. (2017) Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis. ClinicoEconomics and Outcomes Research 9, pages 251-260.
Read now
Read now
José Manuel Garcia-Dominguez, Delicias Muñoz, Marta Comellas, Irmina Gonzalbo, Luis Lizán & Carlos Polanco Sánchez. (2016) Patient preferences for treatment of multiple sclerosis with disease-modifying therapies: a discrete choice experiment. Patient Preference and Adherence 10, pages 1945-1956.
Read now
Read now
Joan M Nolla, Manuel Rodríguez, Emilio Martin-Mola, Enrique Raya, Isabel Ibero, Gonzalo Nocea, Belén Aragon, Luis Lizán & Miriam Prades. (2016) Patients’ and rheumatologists’ preferences for the attributes of biological agents used in the treatment of rheumatic diseases in Spain. Patient Preference and Adherence 10, pages 1101-1113.
Read now
Read now
Carlos Morillas, Rosa Feliciano, Pablo Fernández Catalina, Carla Ponte, Marta Botella, João Rodrigues, Enric Esmatjes, Javier Lafita, Luis Lizán, Ignacio Llorente, Cristóbal Morales, Jorge Navarro-Pérez, Domingo Orozco-Beltran, Silvia Paz, Antonio Ramirez de Arellano, Cristina Cardoso & Maribel Tribaldos Causadias. (2015) Patients’ and physicians’ preferences for type 2 diabetes mellitus treatments in Spain and Portugal: a discrete choice experiment. Patient Preference and Adherence 9, pages 1443-1458.
Read now
Read now
Articles from other publishers (6)
Brittney Lager, Jacob Liseno, Ivan Božin, Sarah M. England, Sai L. Shankar, Jason P. Mendoza & James B. Lewin. (2022) Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis. Neurology and Therapy 12:1, pages 145-159.
Crossref
Crossref
Steven Simoens. (2022) Societal economic burden of multiple sclerosis and cost-effectiveness of disease-modifying therapies. Frontiers in Neurology 13.
Crossref
Crossref
Martin S. Weber, Mathias Buttmann, Sven G. Meuth, Petra Dirks, Erwan Muros-Le Rouzic, Julius C. Eggebrecht, Stefanie Hieke-Schulz, Jost Leemhuis & Tjalf Ziemssen. (2022) Safety, Adherence and Persistence in a Real-World Cohort of German MS Patients Newly Treated With Ocrelizumab: First Insights From the CONFIDENCE Study. Frontiers in Neurology 13.
Crossref
Crossref
Simona Halúsková & Martin Vališ. (2021) Treatment persistence to ocrelizumab and local experience. Neurologie pro praxi 22:3, pages 231-234.
Crossref
Crossref
Kristina F Simacek, John J Ko, Debbie Moreton, Stefan Varga, Kristen Johnson & Bozena J Katic. (2018) The Impact of Disease-Modifying Therapy Access Barriers on People With Multiple Sclerosis: Mixed-Methods Study. Journal of Medical Internet Research 20:10, pages e11168.
Crossref
Crossref
Jing Hao, James Pitcavage, J.B. Jones, Carl Hoegerl & Jove Graham. (2017) Measuring Adherence and Outcomes in the Treatment of Patients With Multiple Sclerosis. Journal of Osteopathic Medicine 117:12, pages 737-747.
Crossref
Crossref